KR20190099469A - 중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트 - Google Patents

중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트 Download PDF

Info

Publication number
KR20190099469A
KR20190099469A KR1020197021001A KR20197021001A KR20190099469A KR 20190099469 A KR20190099469 A KR 20190099469A KR 1020197021001 A KR1020197021001 A KR 1020197021001A KR 20197021001 A KR20197021001 A KR 20197021001A KR 20190099469 A KR20190099469 A KR 20190099469A
Authority
KR
South Korea
Prior art keywords
hydroxybutyrate
composition
macronutrient
pack
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197021001A
Other languages
English (en)
Korean (ko)
Inventor
클로에 구센스
리스 란고우체
그레에트 판 덴 베르그헤
일세 판호레베에크
Original Assignee
카트호리이케 유니버시타이트 로이펜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카트호리이케 유니버시타이트 로이펜 filed Critical 카트호리이케 유니버시타이트 로이펜
Priority claimed from PCT/EP2017/081394 external-priority patent/WO2018114309A1/en
Publication of KR20190099469A publication Critical patent/KR20190099469A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197021001A 2016-12-23 2017-12-04 중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트 Ceased KR20190099469A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438771P 2016-12-23 2016-12-23
US62/438,771 2016-12-23
LU100353 2017-08-01
LU100353 2017-08-01
PCT/EP2017/081394 WO2018114309A1 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Publications (1)

Publication Number Publication Date
KR20190099469A true KR20190099469A (ko) 2019-08-27

Family

ID=60582587

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021001A Ceased KR20190099469A (ko) 2016-12-23 2017-12-04 중환자 치료의 처치에서 사용하기 위한 단독으로의 또는 조합으로의 3-히드록시부티레이트

Country Status (10)

Country Link
US (2) US20190314307A1 (enExample)
EP (1) EP3558291A1 (enExample)
JP (1) JP7174428B2 (enExample)
KR (1) KR20190099469A (enExample)
CN (1) CN110248652B (enExample)
AU (1) AU2017381059B2 (enExample)
BR (1) BR112019012899A2 (enExample)
CA (1) CA3047362A1 (enExample)
CO (1) CO2019007531A2 (enExample)
MX (1) MX390420B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666548B2 (en) 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
US20240269096A1 (en) * 2022-12-31 2024-08-15 American Ketone Therapeutics LLC Rapid Onset Therapeutic Ketosis Enabled by D-BetaHydroxyButyric Acid Systems, Compounds and Methods for Sepsis Protection and Enhanced Medical Recovery
CN117243939B (zh) * 2023-11-14 2025-03-07 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338090C (en) * 1998-07-22 2009-07-14 Metabolix, Inc. Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies
CA2339941A1 (en) * 1998-09-15 2000-03-23 Btg International Limited Use of cyclic esters of r-3-hydroxybutyrate for treatment of metabolic and neural degenerative disorders
DK1648952T3 (en) * 2003-06-03 2018-05-28 The Us Gov As Represented By The Department Of Health And Human Services Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
ES2655367T3 (es) * 2008-08-21 2018-02-19 Oxford University Innovation Limited Bebida que comprende éster de hidroxibutirato y uso médico de la misma
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown

Also Published As

Publication number Publication date
BR112019012899A2 (pt) 2019-12-03
CN110248652B (zh) 2023-05-26
JP2020502202A (ja) 2020-01-23
US20230310353A1 (en) 2023-10-05
CO2019007531A2 (es) 2020-01-17
MX390420B (es) 2025-03-20
US20190314307A1 (en) 2019-10-17
AU2017381059A1 (en) 2019-07-25
AU2017381059B2 (en) 2023-11-30
MX2019007597A (es) 2019-12-19
NZ755274A (en) 2025-09-26
CA3047362A1 (en) 2018-06-28
US12409159B2 (en) 2025-09-09
JP7174428B2 (ja) 2022-11-17
EP3558291A1 (en) 2019-10-30
CN110248652A (zh) 2019-09-17

Similar Documents

Publication Publication Date Title
WO2018114309A1 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
US12409159B2 (en) 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment
Yin et al. AMPK-dependent modulation of hepatic lipid metabolism by nesfatin-1
EP2519234B1 (en) Anaplerotic therapy for alzheimer's disease
Choi et al. Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice
AU2014340303B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
TW201818935A (zh) 治療肝臟疾病之方法
CN107835695A (zh) 用于治疗自闭症的组合物和方法
NZ575655A (en) Nutrient sensor
Idrovo et al. Inhibition of lipogenesis reduces inflammation and organ injury in sepsis
EP3386967A1 (en) Combinations for the treatment of kidney stones
TWI631943B (zh) 治療脂肪肝疾病之方法
Zhang et al. Acetate Administration Ameliorates Streptozotocin‐Induced Hyperglycemia and Adipose Tissue Loss
Ding et al. β-hydroxybutyric acid as a potential therapeutic metabolite for type 2 diabetes mellitus
JP2019522030A (ja) 肝性脳症の治療方法
US20190382336A1 (en) HYPDH Inhibitors and Methods of Use for the Treatment of Kidney Stones
EP3628009A1 (en) Compositions and methods for improving cognition
Pathak Modifying Acetylation in Skeletal Muscle to Improve Health-and Life-Span
US20020197301A1 (en) Animal body fat control
WO2024237316A1 (ja) エポキシ化不飽和脂肪酸の皮膚線維化改善作用
US20180042882A1 (en) C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF FOR TREATING OBESITY, PROMOTING WEIGHT LOSS, AND SUPPORTING WEIGHT MANAGEMENT
Farhan et al. Evaluation of the pharmacological effects of Serratiopeptidase on the central nervous system in mice
EP3934640A1 (en) Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease
WO2020178803A1 (en) Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201130

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230324

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230905

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230324

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230905

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230623

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201130

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240130

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231204

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230905

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230623

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230324

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201130

X601 Decision of rejection after re-examination